TR study of ‘A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancer (BRAVERY study)"
收藏NIAID Data Ecosystem2026-03-10 收录
官方服务：
资源简介：
Primary outcome(s): cancer-related gene alteration, gene expression, microsatellite instability, BRAF mutant allele frequency
创建时间：
2018-04-15
